Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SMX | Smx (Security Matters) Public | $33.96 | $14.68 | 76.14% | 16.5M | $20M | $3.12$34,234.80 |
| RGC | Regencell Bioscience | $52.88 | $19.85 | 60.10% | 3.2M | $16B | $0.09$83.60 |
| NVVE | Nuvve | $3.51 | $1.31 | 59.55% | 79.8M | $2.9M | $1.98$200.80 |
| GLUE | Monte Rosa Therapeutics | $23.28 | $7.27 | 45.41% | 23.2M | $1.0B | $3.50$25.15 |
| ERAS | Erasca | $5.17 | $1.54 | 42.42% | 41.2M | $1.0B | $1.01$6.49 |
| MNTS | Momentus | $13.90 | $4.07 | 41.40% | 25.6M | $14M | $4.73$160.65 |
| ABVE | Above Food Ingredients | $2.46 | $0.67 | 37.43% | 6.4M | $92M | $0.25$6.56 |
| VTYX | Ventyx Biosciences | $13.73 | $3.68 | 36.62% | 28M | $717M | $0.78$25.00 |
| TGL | Treasure Global | $8.61 | $2.28 | 36.02% | 4.5M | $9.7M | $4.51$380.00 |
| ZNTL | Zentalis Pharmaceuticals | $2.42 | $0.64 | 35.95% | 4.7M | $129M | $1.01$3.06 |
Related Articles
Featured Article
Why Shattuck Labs Stock Soared in December
Eric Volkman|Jan 5, 2026
Buttressed by a significant amount of fresh capital, the company is showing progress in the early development of its top investigational drug.
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Selena Maranjian|Nov 24, 2025
Is the stock likely to keep surging? The answer seems pretty clear.
Up 126% in 3 Days, Is Tango Therapeutics a Buy Right Now?
Alex Carchidi|Aug 17, 2023
Remember that past performance doesn't predict future returns.
Advertisement
Could This New Partnership Help Realogy Grow Its Bottom Line?
Matt Frankel, CFP and Jason Hall|Dec 16, 2021
The real estate brokerage giant is teaming up with a big luxury brand.
My Take: 4 Cheap Growth Stocks to Buy This Week
Jose Najarro|Jun 21, 2021
These four stocks are providing solutions in innovative markets.
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
Jia Jie Chen|Apr 21, 2021
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
This 2020 Biotech IPO Is Poised to Break Out in 2021
Patrick Bafuma|Apr 2, 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
This Was the Top-Performing IPO in 2020
Rick Munarriz|Dec 28, 2020
A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.
Up 1,600% In 2 Days, Is It Too Late To Buy This Hot Biotech Stock?
Zhiyuan Sun|Dec 10, 2020
Greenwich LifeSciences made investors rich overnight. Is there any growth left in this breast cancer treatment developer?
A "Blue Wave" Could Be Coming: 5 Stocks to Buy
Billy Duberstein|Oct 18, 2020
If Democrats take the House, Senate, and presidency, the following five stocks stand to benefit from new stimulus legislation proposed by the Biden-Harris campaign.
